CELLINK announces strategic partnership with Carcinotech to advance 3D-bioprinting technology for cancer research

CELLINK, a leading provider of innovative biomaterials and technologies for 3D bioprinting applications in the life sciences, announced a collaboration with Carcinotech, which focuses on the production of cancer research models for drug testing, cancer drug discovery and the study of cancer biology. This collaboration seeks to use CELLINK’s patent-pending bioinks to help Carcinotech develop its proprietary 3D-bioprinted cancer research model that will mimic cancer systems found in the human body on a micro-size chip.

Read the full article here

About Us

Carcinotech has pioneered the development of assay-ready, 3D-bioprinted tumours derived from patient biopsies for oncology drug discovery and development.